Completed PHASE3 INTERVENTIONAL NCT00029861

Obese Patients With or Without Comorbidities (RIO-North America)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities

Sponsor: Sanofi

Conditions Obesity Weight Loss

Interventions Rimonabant (SR141716)

Updated 7 times since 2017 Last updated: Apr 17, 2009 Started: Aug 31, 2001 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00029861, this PHASE3 trial focuses on Obesity and Weight Loss and remains completed. Sponsored by Sanofi, it has been updated 7 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Atlanta, United States , Austin, United States , Baton Rouge, United States , Beavercreek, United States , Birmingham, United States , Charlotte, United States , Chattanooga, United States , Cincinnati, United States , Columbus, United States and 39 more locations